- Home
- ANGO vs AOMR Comparison
ANGO vs AOMR Comparison
Compare ANGO & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- AOMR
- Stock Information
- Founded
- ANGO 1988
- AOMR 2018
- Country
- ANGO United States
- AOMR United States
- Employees
- ANGO N/A
- AOMR N/A
- Industry
- ANGO Medical/Dental Instruments
- AOMR Real Estate Investment Trusts
- Sector
- ANGO Health Care
- AOMR Real Estate
- Exchange
- ANGO Nasdaq
- AOMR Nasdaq
- Market Cap
- ANGO 271.1M
- AOMR 240.9M
- IPO Year
- ANGO 2004
- AOMR 2021
- Fundamental
- Price
- ANGO $6.95
- AOMR $9.40
- Analyst Decision
- ANGO Strong Buy
- AOMR Buy
- Analyst Count
- ANGO 4
- AOMR 6
- Target Price
- ANGO $12.00
- AOMR $12.10
- AVG Volume (30 Days)
- ANGO 413.1K
- AOMR 124.1K
- Earning Date
- ANGO 01-03-2025
- AOMR 11-06-2024
- Dividend Yield
- ANGO N/A
- AOMR 13.76%
- EPS Growth
- ANGO N/A
- AOMR N/A
- EPS
- ANGO N/A
- AOMR 2.91
- Revenue
- ANGO $292,726,000.00
- AOMR $94,441,000.00
- Revenue This Year
- ANGO N/A
- AOMR N/A
- Revenue Next Year
- ANGO $7.69
- AOMR $29.25
- P/E Ratio
- ANGO N/A
- AOMR $3.18
- Revenue Growth
- ANGO N/A
- AOMR 455.18
- 52 Week Low
- ANGO $5.26
- AOMR $8.88
- 52 Week High
- ANGO $8.25
- AOMR $13.32
- Technical
- Relative Strength Index (RSI)
- ANGO 50.87
- AOMR 42.77
- Support Level
- ANGO $6.63
- AOMR $9.18
- Resistance Level
- ANGO $6.98
- AOMR $10.11
- Average True Range (ATR)
- ANGO 0.29
- AOMR 0.23
- MACD
- ANGO -0.02
- AOMR 0.01
- Stochastic Oscillator
- ANGO 37.78
- AOMR 42.28
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.